KaloBios announces retirement of CFO

Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email | Twitter) and we will feature it here each Friday.

KaloBios announces retirement of CFO

On the heels of KaloBios going public, Jeffrey Cooper is retiring as chief financial officer of the San Francisco-based antibody developer. Cooper's retirement is effective Dec. 31. He will stay at the company full-time until mid-November and as a part-time adviser until the end of the calendar year. Cooper joined KaloBios in July 2012. Previously, he served as senior vice president and chief financial officer of BioMarin Pharmaceutical ($BMRN). Release


KaloBios Pharmaceuticals
Jeffrey Cooper is retiring from the position of chief financial officer.


MicroBiome Therapeutics
Steve Orndorff is the new CEO of MicroBiome.

Biotech

NuMe Health has changed its name to MicroBiome Therapeutics and has hired Steve Orndorff as CEO. Previously, Orndorff was CEO of Ariel Pharmaceuticals. Release

James Mazzo was appointed Neurotech Pharmaceuticals' executive chairman. Mazzo was formerly CEO of Abbott Medical Optics, is an operating partner at Versant Ventures and was recently named chairman and CEO of AcuFocus, a Versant portfolio company. Release

Vincent Aurentz has joined HemoShear as the company's chief business officer. Aurentz previously was executive vice president of the Customer Solutions Business at Quintiles ($Q). Release

Hyperion Therapeutics ($HPTX) has hired Larry J. Singer as vice president, Manufacturing. Previously, Singer held positions at Elan Pharmaceuticals ($ELN), Gilead Sciences ($GILD), Dey Laboratories, Syntex and Wyeth Laboratories. Release

Lewis Barrett has joined Synthetic Biologics ($SYN) as its senior vice president, Commercial Strategy. Barrett is the former assistant vice president of Established Products at Pfizer ($PFE) and vice president global business manager of Infectious Diseases at Wyeth Pharmaceuticals. Release

NeoStem has appointed Douglas Losordo as chief medical officer. Most recently, Losordo was vice president, New Therapies Development, Regenerative Medicine and Baxter Ventures at Baxter International ($BAX). Release

Gary Altman is taking on the positions of president, CEO and a member of the board of directors at Caldera Pharmaceuticals. Release

Clearside Biomedical named Glenn Noronha its executive vice president of research and development. Release

AIT Laboratories announced that R. Matthew Neff would be its new CEO and president, as well as retain his role as chairman of the board. Release

Tengion promoted A. Brian Davis to be the company's senior vice president of finance in addition to his current position as chief financial officer. Release

Pharma

Merz North America appointed John Donofrio as the company's chief financial officer and head of North American business development. Release

Deborah DuFresne joined InnoPharma as vice president of strategic portfolio selection and management. DuFresne was formerly a senior director at Impax Laboratories. Release

Alan Copa joined Novum Pharmaceutical Research Services as the company's vice president to lead its clinical expansion. Release

Drug Delivery

Elite Pharmaceuticals brought on Nasrat Hakim as its president, CEO and member of the board of directors. Hakim previously worked for Actavis ($ACT), Watson ($WPI) and Alpharma in senior management. Release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.